title: Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells.
abstract: OBJECTIVE
  Drug resistance is the primary cause of failure in the treatment of cancers. It has been suggested that the enhancement of DNA repair capability may be responsible for the drug resistance of the tumour cells, and poly(ADP-ribosyl)ation plays an important role in DNA repair. This study investigated the effect of PARP inhibitor 3-aminobenzamide (3-AB) on the cisplatin resistance and proliferation of the cisplatin-resistant ovarian cancer C13 FNx01 cells in vitro.
  
  
  METHODS
  C13 FNx01 cells were treated with various concentrations of 3-AB in vitro. MTT assay was used to determine the effect of 3-AB on the cisplatin sensitivity and proliferation of cells. The expression levels of PARP-1 mRNA and protein in the C13 FNx01 cells were examined using reverse transcription-polymerase chain reaction (RT-PCR) and Western blot, and changes caused by 3-AB treatment were investigated. Immunofluorescence microscopy was used to detect the localization and expression of the PARP-1 proteins before and after treatment with 5 mmol/l 3-AB.
  
  
  RESULTS
  The inhibitory ratio and the cisplatin sensitivity of C13 FNx01 cells significantly increased with the increase of the concentration of 3-AB (P<0.05). The RT-PCR analysis revealed that the expression of PARP-1 mRNA was decreased when platinum (Pt) and 3-AB were combined. The expression levels of PARP-1 protein were decreased by 23.15 ± 2.53, 59.11 ± 2.23 and 73.24 ± 3.88 per cent, respectively, in C13 FNx01 cells with the increase of the concentration of 3-AB (P<0.05). The immunofluorescence microscopy results indicated that the expression level of PARP-1 protein was significantly decreased after treatment with 3-AB (P,<0.05).
  
  
  CONCLUSIONS
  3-AB inhibited the proliferation activity of C13 FNx01 cells, and increased the cellular sensitivity to cisplatin. Our findings show that the PARP inhibitor 3-AB can downregulate the expression of PARP-1 at transcriptional and translational levels in C13 FNx01 cells.
authors: Department of Obstetrics & Gynecology & Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, PR China.
authors: Jingjing
authors: J
authors: Zhang
authors: Yanyan
authors: Y
authors: Kan
authors: Yongjie
authors: Y
authors: Tian
authors: Zhe
authors: Z
authors: Wang
authors: Jie
authors: J
authors: Zhang
mesh_terms: D017209:Apoptosis; D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*
chemical_list: D001549:Benzamides; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C025160:3-aminobenzamide; D011065:Poly(ADP-ribose) Polymerases; D002945:Cisplatin
references: Oncol Lett. 2012 Jan;3(1):66-74
references: 22740858
references: Oncol Rep. 2011 May;25(5):1399-405
references: 21399878
references: Int J Cancer. 2011 Jan 15;128(2):251-65
references: 20853319
references: J Atheroscler Thromb. 2009 Oct;16(5):641-53
references: 19776495
references: Genome Integr. 2010 May 26;1(1):5
references: 20678253
references: Bioorg Med Chem. 2008 Dec 1;16(23):10121-8
references: 18977144
references: Oncogene. 2002 Feb 7;21(7):1108-16
references: 11850828
references: BMC Cancer. 2011 Jan 28;11:41
references: 21276234
references: Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008765
references: 23450588
references: Cancer Res. 2003 Mar 15;63(6):1311-6
references: 12649192
references: Mol Vis. 2012;18:317-29
references: 22355243
references: Nucleic Acids Res. 2006;34(21):6170-82
references: 17088286
references: Acta Clin Belg. 2011 Jan-Feb;66(1):2-9
references: 21485757
references: Am J Pathol. 2011 Mar;178(3):946-55
references: 21356345
references: Carcinogenesis. 2010 Mar;31(3):388-93
references: 20015866
references: Br J Cancer. 2008 Mar 25;98(6):1085-93
references: 18349819
references: Nucleic Acids Res. 2011 Jul;39(12):5045-56
references: 21398629
references: Oncologist. 2009 Jul;14(7):706-16
references: 19592450
references: Proc Natl Acad Sci U S A. 2010 May 18;107(20):9129-34
references: 20439749
references: Genes Chromosomes Cancer. 2011 Jan;50(1):13-24
references: 20931645
references: N Engl J Med. 2009 Oct 8;361(15):1475-85
references: 19812404
references: Cancer Res. 2010 Oct 15;70(20):8088-96
references: 20940411
references: Methods Enzymol. 2006;409:493-510
references: 16793420
references: BMC Evol Biol. 2010 Oct 13;10:308
references: 20942953
references: Clin Cancer Res. 2007 May 15;13(10):3033-42
references: 17505006
references: Clin Cancer Res. 2009 Jan 15;15(2):607-12
references: 19147766
references: Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1545-53
references: 16632544
references: Mol Cancer Ther. 2009 Jul;8(7):2015-26
references: 19567822
references: Cancer Lett. 2011 Feb 1;301(1):47-56
references: 21093979
references: Gan To Kagaku Ryoho. 2010 Jul;37(7):1187-91
references: 20647696
references: World J Clin Oncol. 2011 Feb 10;2(2):73-9
references: 21603316